Health policy has quietly become a stock-moving variable in 2026, and the figures are significant enough to matter. Approximately 2.6 million Americans discontinued ACA marketplace coverage this year after increased pandemic-era subsidies ended at the end of 2025, with health policy experts predicting that total enrollment would decrease to between 16.5 million and 17.5 million by year-end. Meanwhile, the Urban Institute has projected that 4.8 million more people will be uninsured in 2026 as a direct consequence of the lapsed subsidies, with certain HealthCare.gov-reliant states witnessing enrollment losses of 20% or more.
The Selloff
Whether this translates into fewer elective medical treatments is now a hotly debated topic in the healthcare industry, with Intuitive Surgical, Inc. (NASDAQ:ISRG) emerging as the evident casualty. The company’s shares plunged more than 12% before the bell on July 17, despite Intuitive maintaining its global procedure-growth prediction for its da Vinci surgical robots. Instead, the selloff was driven by the company’s own admission that changes in insurance coverage could impact demand.
US da Vinci procedure growth slowed to roughly 12% in the second quarter, down from where Intuitive Surgical, Inc. (NASDAQ:ISRG) expected to be at the beginning of the year, with a focus on surgeries that patients may defer. On the July 16 call, CEO David Rosa told analysts that customer conversations indicated that fluctuating patient coverage and premium dynamics affect “when patients seek care,” as opposed to if they seek it at all.
A Sector Split on the ACA Question
That reaction came at an awkward time, as a highly public disagreement was already taking place in the sector. Abbott, a major medical device and diagnostics manufacturer, had argued recently that blaming industry-wide procedure weakness on ACA disenrollment was a “flawed assumption.” HCA Healthcare, the largest for-profit hospital operator in the United States, took the opposite stance, warning earlier of lower surgical demand and an increase in uninsured patients when pandemic-era subsidies expired.
Intuitive’s own results now appear to support the HCA side of the argument, at least in procedures when patients can choose to delay. Stifel’s response immediately reflected the tension: the firm reduced its price objective to $550 from $670 on July 17 while keeping a Buy rating on the company’s shares, despite Intuitive Surgical, Inc. (NASDAQ:ISRG) exceeding expectations in revenue, earnings, system placements, and procedure growth in the same quarter. Both US procedure and installed-base growth have slowed since the 2020-2021 COVID era, with management blaming the slowdown on ACA disenrollment and the basic law of large numbers as the installed base matures.
The Valuation Shift Nobody is Talking About
The valuation shift underlying all of this is another intriguing long-term indicator. ISRG’s forward P/E ratio has fallen to about 33x as of July 17, down dramatically from a five-year high of 96x and currently near the low end of its own five-year range. The company has traded at a structural premium to medical device rivals for the majority of the last decade, but that premium has essentially dissipated, with its current multiple now about in line with the peer group average of about 35x.
Institutional positioning was already softening before this quarter’s ACA-related warning gave the market a solid reason to sell. According to Insider Monkey’s Q1 2026 database, 103 elite funds held Intuitive Surgical, Inc. (NASDAQ:ISRG) at quarter-end, down from 109 the previous quarter, a decline that predates both Abbott’s “flawed assumption” pushback on the ACA thesis and the earnings reaction.
Insider Monkey’s Bottom line
NZS Growth Equity Strategy stated the following regarding Intuitive Surgical, Inc. (NASDAQ:ISRG) in its Q2 2026 investor update:
“Only Real Estate and Healthcare contributed negatively to absolute returns, but Materials and Financials lagged. Intuitive Surgical, Inc. (NASDAQ:ISRG) was the top individual detractor to absolute returns in the quarter. While fundamentals remain solid for Intuitive Surgical, the stock’s multiple has not been immune from the broad de-rating in “quality growth” stocks we’ve seen outside of the AI ecosystem.”
The market’s brutal treatment of Intuitive Surgical, Inc. (NASDAQ:ISRG) represents a classic timeline disconnect. While ACA subsidy lapses provide significant short-term friction for deferrable domestic treatments, the fundamental thesis for the world’s leading robotic surgery company remains unchanged. Recurring revenue, derived from instruments, accessories, and service contracts, now accounts for 85% of overall sales, producing predictable cash flows across a global installed base of around 13,000 units.
Moreover, increased international procedure growth of 20% and widespread adoption of the next-generation da Vinci 5 platform serve as effective counterweights to temporary US coverage dynamics. Intuitive Surgical, which trades at 33x forward earnings and matches generic medtech peers despite its solid moat, has an extraordinary risk-reward profile. Long-term institutional investors should take advantage of this policy-induced weakness to establish strong stakes in a leading growth monopoly.
While we acknowledge the risk and potential of ISRG as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than ISRG and that has 10,000% upside potential, check out our report about this cheapest AI stock.
READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years
Disclosure: None. Follow Insider Monkey on Google News.
Hedge Fund Resource Center